A Phase 3 interventional study of Obinutuzumab and MMF in Lupus Nephritis, sponsored by Hoffmann-La Roche. Active, not recruiting at 74 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 8th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Brazil, Canada and 9 more countries
Ages 5–17
By country, each count listing its studies:
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 52 across the 11 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80. After study unblinding, participants may be eligible for further open-label obinutuzumab treatment.
Drug: Obinutuzumab · Drug: MMF · Drug: Prednisone · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine
Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80. Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80. After study unblinding, participants may be eligible for further open-label obinutuzumab treatment.
Drug: Obinutuzumab · Drug: MMF · Drug: Prednisone · Drug: Placebo · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
Also known as: Gazyva, GA101, RO5072759
MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Percentage of Participants With Complete Renal Response (CRR)
CRR was defined as an achievement of all the following criteria: urinary protein-to-creatinine ratio (UPCR) \<0.5 gram/gram (g/g); estimated glomerular filtration rate (eGFR) \>=85% of baseline, as calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Obinutuzumab and placebo were compared using Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using fully conditional specification (FCS) predicted mean matching method. Percentage have been rounded off.
Time frame: At Week 76
Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76
CRR with successful prednisone was defined as the achievement of CRR at Week 76 with no receipt of prednisone \>7.5 milligrams per day (mg/day) (or equivalent) from Week 64 through Week 76. CRR was defined as achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Time frame: At Week 76
Percentage of Participants Who Achieve a Proteinuric Response
Proteinuric response was defined as an achievement of all the following criteria: UPCR \<0.8 g/g and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Time frame: At Week 76
Mean Change in eGFR
Change in eGFR from baseline to Week 76 was analyzed using Analysis of Covariance (ANCOVA) model with covariates baseline eGFR and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. mL/min/1.73 m\^2 = milliliters per minute per 1.73 square meters. Adjusted mean has been reported.
Time frame: At Week 76
Percentage of Participants Who Experience Death or Renal-related Events
Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value \<60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.
Time frame: From Day 1 to Week 76
Percentage of Participants Who Achieve an Overall Renal Response (ORR)
ORR was defined as achievement of either CRR or PRR. CRR was defined as achievement of all of the criteria: UPCR \<0.5 g/g; eGFR ≥85% of baseline, as calculated using the CKD-EPI equation. PRR was defined as achievement of all of the following criteria: ≥50% reduction in UPCR from baseline; UPCR \<1 g/g (or \<3 g/g if the baseline UPCR was ≥3 g/g); eGFR ≥85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Time frame: At Week 50
Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-F score of 0 (worse score) to 52 (better score). Higher scores indicate less fatigue. Change in FACIT-F score from baseline at Week 76 was analyzed using ANCOVA model with covariates baseline FACIT-F score and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing FACIT-F score after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Time frame: At Week 76
Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer
Anti-dsDNA are types of autoantibodies produced by the immune system and are indicators of lupus. Anti-dsDNA data was log-transformed before analysis. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with upper limit of quantification (ULOQ, 890 international units/milliliter \[IU/mL\]). Adjusted mean has been reported.
Time frame: At Week 50
Change in Complement C3
C3 is a marker of inflammation. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with lower limit of quantification (LLOQ)/2 under composite strategy. LLOQ at the central lab was set for C3 at 0.100 grams/liters (g/L). Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Time frame: At Week 50
Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
The SLEDAI-2K is a 24-item instrument that evaluates clinical symptoms and laboratory markers across nine organ systems and was used to capture changes in lupus-related disease activity. SLE manifestations are assessed by the clinician if present within the last 30 days and added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Higher scores indicate increased disease activity. The analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 105, the highest possible score. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Time frame: At Week 76
Time to Onset of CRR
CRR was defined as an achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.
Time frame: From baseline (Day 1) up to 80.3 weeks
Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria
CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR \<0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by \> 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.
Time frame: At Week 76
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: Up to Week 76
Number of Participants With Adverse Events of Special Interest (AESIs)
An AE was any untoward medical occurrence in participant administered a pharmaceutical product \& which does not necessarily have to have a causal relationship with treatment. It can therefore be any unfavorable \& unintended sign (including abnormal laboratory values/ abnormal clinical test results), symptoms, or disease temporally associated with use of pharmaceutical product, whether or not considered related to product. AESIs included potential drug-induced liver injury that include an elevated alanine transaminase (ALT) \& aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice defined by Hy's law; suspected transmission of an infectious agent by study drug; infusion-related reactions (IRRs); grade 3/higher infections; any hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML); drug-related neutropenia; drug-related thrombocytopenia; gastrointestinal perforations and worsening of pre-existing cardiac conditions
Time frame: Up to Week 76
Number of Participants With Anti-Drug Antibodies (ADAs) Positive Post-Treatment
Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
Time frame: Up to approximately 11 years
Total Peripheral B-Cell (CD19) Count
Time frame: Up to approximately 11 years
Concentration of Obinutuzumab in Serum
Time frame: Up to approximately 11 years
A total of 271 participants with International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis (LN) treated with standard-of-care (SOC) therapy took part in the study across 72 sites in 15 countries. This study consists of blinded treatment with obinutuzumab or placebo, followed by open-label treatment (OLT) with obinutuzumab.
| Milestone | Obinutuzumab | Placebo |
|---|---|---|
| Started | 135 | 136 |
| Safety population | 136 | 132 |
| Completed week 76 assessment | 122 | 120 |
| Completed | 0 | 0 |
| Not completed | 135 | 136 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 5 | 4 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Reason not specified | 0 | 5 |
| Withdrew: Physician decision | 0 | 6 |
| Withdrew: Withdrawal by subject | 10 | 14 |
| Withdrew: Ongoing in the study | 116 | 102 |
CRR was defined as an achievement of all the following criteria: urinary protein-to-creatinine ratio (UPCR) \<0.5 gram/gram (g/g); estimated glomerular filtration rate (eGFR) \>=85% of baseline, as calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Obinutuzumab and placebo were compared using Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using fully conditional specification (FCS) predicted mean matching method. Percentage have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants With Complete Renal Response (CRR) | 46.4 (37.95 to 54.86) | 33.1 (25.18 to 41.00) |
CRR with successful prednisone was defined as the achievement of CRR at Week 76 with no receipt of prednisone \>7.5 milligrams per day (mg/day) (or equivalent) from Week 64 through Week 76. CRR was defined as achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76 | 42.7 (34.32 to 51.09) | 30.9 (23.12 to 38.65) |
Proteinuric response was defined as an achievement of all the following criteria: UPCR \<0.8 g/g and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieve a Proteinuric Response | 55.5 (47.09 to 63.95) | 41.9 (33.62 to 50.20) |
Change in eGFR from baseline to Week 76 was analyzed using Analysis of Covariance (ANCOVA) model with covariates baseline eGFR and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. mL/min/1.73 m\^2 = milliliters per minute per 1.73 square meters. Adjusted mean has been reported.
| mL/min/1.73 m^2 | Obinutuzumab | Placebo |
|---|---|---|
| Mean Change in eGFR | 2.31 ± 2.713 | -1.54 ± 2.706 |
Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value \<60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Experience Death or Renal-related Events | 18.9 (12.11 to 25.61) | 35.6 (27.50 to 43.78) |
ORR was defined as achievement of either CRR or PRR. CRR was defined as achievement of all of the criteria: UPCR \<0.5 g/g; eGFR ≥85% of baseline, as calculated using the CKD-EPI equation. PRR was defined as achievement of all of the following criteria: ≥50% reduction in UPCR from baseline; UPCR \<1 g/g (or \<3 g/g if the baseline UPCR was ≥3 g/g); eGFR ≥85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieve an Overall Renal Response (ORR) | 59.1 (50.80 to 67.43) | 50.7 (42.16 to 59.22) |
The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-F score of 0 (worse score) to 52 (better score). Higher scores indicate less fatigue. Change in FACIT-F score from baseline at Week 76 was analyzed using ANCOVA model with covariates baseline FACIT-F score and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing FACIT-F score after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
| score on a scale | Obinutuzumab | Placebo |
|---|---|---|
| Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | 1.76 ± 1.223 | 3.11 ± 1.212 |
Anti-dsDNA are types of autoantibodies produced by the immune system and are indicators of lupus. Anti-dsDNA data was log-transformed before analysis. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with upper limit of quantification (ULOQ, 890 international units/milliliter \[IU/mL\]). Adjusted mean has been reported.
| Log (IU/mL) | Obinutuzumab | Placebo |
|---|---|---|
| Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer | -0.38 ± 0.100 | -0.01 ± 0.099 |
C3 is a marker of inflammation. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with lower limit of quantification (LLOQ)/2 under composite strategy. LLOQ at the central lab was set for C3 at 0.100 grams/liters (g/L). Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
| g/L | Obinutuzumab | Placebo |
|---|---|---|
| Change in Complement C3 | 0.20 ± 0.030 | 0.06 ± 0.030 |
The SLEDAI-2K is a 24-item instrument that evaluates clinical symptoms and laboratory markers across nine organ systems and was used to capture changes in lupus-related disease activity. SLE manifestations are assessed by the clinician if present within the last 30 days and added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Higher scores indicate increased disease activity. The analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 105, the highest possible score. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
| score on a scale | Obinutuzumab | Placebo |
|---|---|---|
| Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) | -5.63 ± 1.456 | -5.51 ± 1.432 |
CRR was defined as an achievement of all the following criteria: UPCR \<0.5 g/g; eGFR \>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.
| weeks | Obinutuzumab | Placebo |
|---|---|---|
| Time to Onset of CRR | 76.4 (76.1 to 77.4) | 80.3 (76.3 to NA) |
CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR \<0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by \> 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria | 46.4 (37.90 to 54.85) | 33.1 (25.18 to 41.00) |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
| Participants | Obinutuzumab | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 126 | 117 |
An AE was any untoward medical occurrence in participant administered a pharmaceutical product \& which does not necessarily have to have a causal relationship with treatment. It can therefore be any unfavorable \& unintended sign (including abnormal laboratory values/ abnormal clinical test results), symptoms, or disease temporally associated with use of pharmaceutical product, whether or not considered related to product. AESIs included potential drug-induced liver injury that include an elevated alanine transaminase (ALT) \& aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice defined by Hy's law; suspected transmission of an infectious agent by study drug; infusion-related reactions (IRRs); grade 3/higher infections; any hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML); drug-related neutropenia; drug-related thrombocytopenia; gastrointestinal perforations and worsening of pre-existing cardiac conditions
| Participants | Obinutuzumab | Placebo |
|---|---|---|
| IRRs | 21 | 15 |
| Grade 3-5 infection | 21 | 9 |
| Any Hepatitis B reactivation and PML | 0 | 0 |
| Drug related Neutropenia | 17 | 5 |
| Drug related Thrombocytopenia | 1 | 0 |
| Gastrointestinal Perforations | 0 | 0 |
| Worsening of pre-existing Cardiac Conditions | 0 | 2 |
| Hy's Law | 0 | 0 |
| Suspected Transmission of an Infectious Agent by the Study Drug | 0 | 0 |
Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to Week 76 Data collected up to the primary completion date (Up to Week 76) is reported. Data collection post Week 76 is still ongoing. Final data will be reported 1 year after the study completion date. As pre-specified in the SAP, safety data were to be provided for obinutuzumab (combined treatment groups) and placebo groups. AE data were collected for all Obinutuzumab participants together, without regard to or information of the specific Obinutuzumab group participants they were part of.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab | 5/136 (3.7%) | 44/136 (32.4%) | 107/136 (78.7%) |
| Placebo | 4/132 (3%) | 24/132 (18.2%) | 94/132 (71.2%) |
| Event | Obinutuzumab | Placebo |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 7/136 | 0/132 |
| NeutropeniaBlood and lymphatic system disorders | 4/136 | 0/132 |
| COVID-19Infections and infestations | 4/136 | 1/132 |
| PneumoniaInfections and infestations | 4/136 | 3/132 |
| Urinary tract infectionInfections and infestations | 4/136 | 2/132 |
| GastroenteritisInfections and infestations | 3/136 | 2/132 |
| Acute kidney injuryRenal and urinary disorders | 3/136 | 2/132 |
| CholecystitisHepatobiliary disorders | 0/136 | 2/132 |
| Nephrotic syndromeRenal and urinary disorders | 1/136 | 2/132 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/136 | 2/132 |
| Event | Obinutuzumab | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 35/136 | 30/132 |
| DiarrhoeaGastrointestinal disorders | 28/136 | 21/132 |
| Urinary tract infectionInfections and infestations | 19/136 | 15/132 |
| Infusion related reactionInjury, poisoning and procedural complications | 19/136 | 14/132 |
| Upper respiratory tract infectionInfections and infestations | 16/136 | 13/132 |
| BronchitisInfections and infestations | 13/136 | 11/132 |
| NeutropeniaBlood and lymphatic system disorders | 12/136 | 4/132 |
| HeadacheNervous system disorders | 12/136 | 8/132 |
| NauseaGastrointestinal disorders | 8/136 | 11/132 |
| VomitingGastrointestinal disorders | 10/136 | 11/132 |
Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, demographic and baseline characteristics were to be provided for obinutuzumab (combined treatment groups) and placebo groups.
| Age, Continuous(years) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Mean | 33.0 ± 10.5 | 32.7 ± 10.0 | 32.9 ± 10.2 |
| Sex: Female, Male(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Female | 114 | 115 | 229 |
| Male | 21 | 21 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 71 | 85 | 156 |
| Not Hispanic or Latino | 54 | 48 | 102 |
| Unknown or Not Reported | 10 | 3 | 13 |
| Race (NIH/OMB)(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 25 | 26 | 51 |
| Asian | 9 | 7 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 20 | 40 |
| White | 65 | 64 | 129 |
| More than one race | 11 | 9 | 20 |
| Unknown or Not Reported | 5 | 10 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Aug 2020 to primary completion in Aug 2024, 48 months.
Results were first posted in Nov 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab